Key result
Tirofiban administration in a 57-year-old man with NSTEMI resulted in profound thrombocytopenia, with platelet counts dropping from 226,000/mcL to 1,000/mcL within 30 hours.
Why the study?
Although thrombocytopenia after glycoprotein IIb/IIIa antagonist administration is relatively low, it can lead to fatal consequences.
Case Report (n=1)
No
Tirofiban can induce acute, profound, and potentially life-threatening thrombocytopenia within hours of administration, necessitating frequent platelet monitoring.
Platelet glycoprotein IIB/IIIA antagonists are potent inhibitors of platelet aggregation. Although the incidence of thrombocytopenia following their administration is relatively low, it can sometimes lead to fatal consequences. We report a case of a 57-year-old gentleman presenting with non-ST elevation myocardial infarction complicated with tirofiban-induced profound thrombocytopenia that developed within 12 hours of administration. Given the high risk of acute-onset thrombocytopenia following treatment with glycoprotein IIb/IIIa inhibitors, platelet count monitoring is highly encouraged at frequent intervals. This case highlights the importance of early detection and treatment of thrombocytopenia.
No takes yet. Share an insight, caveat, or question.
Achkar et al. (2025) conducted a case report in Non-ST elevation myocardial infarction (NSTEMI) and tirofiban-induced profound thrombocytopenia (n=1). Tirofiban was evaluated on Development of profound thrombocytopenia. Tirofiban administration in a 57-year-old man with NSTEMI resulted in profound thrombocytopenia, with platelet counts dropping from 226,000/mcL to 1,000/mcL within 30 hours.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: